{"id":"lysergide","rwe":[{"pmid":"41213204","year":"2026","title":"Development and validation of a simple and fast method for routine analysis of new synthetic opioids and hallucinogens in whole blood using protein precipitation and UHPLC-MS/MS.","finding":"","journal":"Forensic science international","studyType":"Clinical Study"},{"pmid":"40906494","year":"2025","title":"Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.","finding":"","journal":"JAMA","studyType":"Clinical Study"},{"pmid":"37354215","year":"2023","title":"Ergometrine stimulates histamine H(2) receptors in the isolated human atrium.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"30544085","year":"2019","title":"Use of the Randox Evidence Investigator immunoassay system for near-body drug screening during post-mortem examination in 261 forensic cases.","finding":"","journal":"Forensic science international","studyType":"Clinical Study"},{"pmid":"27599655","year":"2016","title":"Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.","finding":"","journal":"The Lancet. Infectious diseases","studyType":"Clinical Study"}],"tags":[{"label":"lysergide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"HTR1A","category":"gene"},{"label":"HTR7","category":"gene"},{"label":"Active","category":"status"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Hallucinogens","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"},{"label":"Serotonin Receptor Agonists","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":212.611,"date":"","count":64,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=213)"},{"llr":147.371,"date":"","count":37,"signal":"Drug dependence","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=147)"},{"llr":114.473,"date":"","count":36,"signal":"Intentional product misuse","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=114)"},{"llr":112.151,"date":"","count":21,"signal":"Alcohol abuse","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=112)"},{"llr":111.314,"date":"","count":23,"signal":"Substance abuse","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=111)"}],"commonSideEffects":[{"effect":"Drug abuse","drugRate":"LLR 213","severity":"common"},{"effect":"Drug dependence","drugRate":"LLR 147","severity":"common"},{"effect":"Intentional product misuse","drugRate":"LLR 114","severity":"common"},{"effect":"Alcohol abuse","drugRate":"LLR 112","severity":"common"},{"effect":"Substance abuse","drugRate":"LLR 111","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"delysid","offLabel":[],"synonyms":["lysergide","D-Lysergic acid diethylamide","delysid","dextrolysergic acid diethylamide","LSD","lysergic acid diethylamide","d-LSD"],"timeline":[{"date":"1957-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Delysid (LYSERGIDE) is a small molecule lysergide that targets the 5-hydroxytryptamine receptor 2A. Its mechanism of action is not FDA-approved, and it is not commercially available. As a result, there is limited information available on its approved indications, half-life, bioavailability, generic manufacturers, and commercial status. Delysid is not a widely recognized or approved medication, and its development and commercialization status are unclear. Further research is needed to understand its potential therapeutic applications and safety considerations.","approvals":[{"date":"1957-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Delysid","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"},{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR5A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 5A","protein":"5-hydroxytryptamine receptor 5A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"HTR1E","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1E","protein":"5-hydroxytryptamine receptor 1E"}],"modality":"Small Molecule","drugClass":"lysergide","explanation":"Imagine your brain cells are like locks, and serotonin is the key that unlocks them. Delysid is a special key that fits into a specific lock, called the 5-hydroxytryptamine receptor 2A, which helps regulate mood and other functions. By binding to this lock, Delysid can influence how serotonin works in the brain.","oneSentence":"Delysid works by binding to the 5-hydroxytryptamine receptor 2A, a subtype of serotonin receptor.","technicalDetail":"Delysid acts as a partial agonist at the 5-hydroxytryptamine receptor 2A, modulating the downstream signaling pathways involved in mood regulation and other physiological processes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1621","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LYSERGIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LYSERGIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:27:32.048925","biosimilars":[],"competitors":[{"drugName":"acebutolol","drugSlug":"acebutolol","fdaApproval":"1984-12-28","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"arbutamine","drugSlug":"arbutamine","fdaApproval":"1997-09-12","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"arformoterol","drugSlug":"arformoterol","fdaApproval":"2006-10-06","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atenolol","drugSlug":"atenolol","fdaApproval":"1981-08-19","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"betaxolol","drugSlug":"betaxolol","fdaApproval":"1985-08-30","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bisoprolol","drugSlug":"bisoprolol","fdaApproval":"1992-07-31","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lysergide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acebutolol","brandName":"acebutolol","genericName":"acebutolol","approvalYear":"1984","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"arbutamine","brandName":"arbutamine","genericName":"arbutamine","approvalYear":"1997","relationship":"same-target"},{"drugId":"arformoterol","brandName":"arformoterol","genericName":"arformoterol","approvalYear":"2006","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atenolol","brandName":"atenolol","genericName":"atenolol","approvalYear":"1981","relationship":"same-target"},{"drugId":"betaxolol","brandName":"betaxolol","genericName":"betaxolol","approvalYear":"1985","relationship":"same-target"},{"drugId":"bisoprolol","brandName":"bisoprolol","genericName":"bisoprolol","approvalYear":"1992","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07490405","phase":"NA","title":"Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","status":"NOT_YET_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-04-01","conditions":["Liver Cirrhosis"],"enrollment":140,"completionDate":"2036-04-01"},{"nctId":"NCT07309471","phase":"NA","title":"Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-03-06","conditions":["LSD Reaction"],"enrollment":24,"completionDate":"2028-07"},{"nctId":"NCT05407064","phase":"PHASE2","title":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","status":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","startDate":"2022-08-24","conditions":["Anxiety Generalized"],"enrollment":198,"completionDate":"2023-11-27"},{"nctId":"NCT05200936","phase":"PHASE2","title":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","status":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","startDate":"2021-12-17","conditions":["ADHD","Attention Deficit Disorder"],"enrollment":53,"completionDate":"2023-12-04"},{"nctId":"NCT05964647","phase":"PHASE1","title":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-02-01","conditions":["Healthy"],"enrollment":20,"completionDate":"2025-06-30"},{"nctId":"NCT07164287","phase":"","title":"Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Geneva","startDate":"2020-06-01","conditions":["Major Depressive Disorder (MDD)","Anxiety Disorders","Substance Use Disorder (SUD)","PTSD - Post Traumatic Stress Disorder"],"enrollment":376,"completionDate":"2025-09-30"},{"nctId":"NCT07189299","phase":"NA","title":"Microdosing LSD in Women With Premenstrual Disorders","status":"NOT_YET_RECRUITING","sponsor":"Friederike Holze","startDate":"2025-10-01","conditions":["PMS","PMDD"],"enrollment":150,"completionDate":"2030-01-01"},{"nctId":"NCT05883540","phase":"PHASE2","title":"Lysergic Acid Diethylamide (LSD) in Palliative Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-06-09","conditions":["Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress"],"enrollment":60,"completionDate":"2028-05"},{"nctId":"NCT07061886","phase":"EARLY_PHASE1","title":"Drug Effects on Mood and Behavior - Expectancy","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-06-26","conditions":["LSD"],"enrollment":48,"completionDate":"2026-06-05"},{"nctId":"NCT07017478","phase":"EARLY_PHASE1","title":"Mood Effects of Serotonin Agonists: Depression","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-06-09","conditions":["LSD","Major Depressive Disorder","Depression"],"enrollment":48,"completionDate":"2026-06-01"},{"nctId":"NCT06557239","phase":"","title":"Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy","status":"COMPLETED","sponsor":"Tatiana Aboulafia Brakha","startDate":"2024-08-05","conditions":["Depression, Anxiety"],"enrollment":10,"completionDate":"2024-12-11"},{"nctId":"NCT03866252","phase":"PHASE2","title":"LSD Therapy for Persons Suffering From Major Depression","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-11-01","conditions":["Major Depressive Disorder"],"enrollment":60,"completionDate":"2022-12-01"},{"nctId":"NCT05477459","phase":"PHASE2","title":"LSD to Improve Cluster Headache Impact Trial","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-04-16","conditions":["Chronic Cluster Headache"],"enrollment":65,"completionDate":"2027-04"},{"nctId":"NCT05570708","phase":"NA","title":"The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training","status":"ENROLLING_BY_INVITATION","sponsor":"Felix Mueller","startDate":"2022-10-25","conditions":["Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD"],"enrollment":48,"completionDate":"2029-06-01"},{"nctId":"NCT05177419","phase":"PHASE1","title":"Effects of LSD on Neuroplasticity in Healthy Subjects","status":"COMPLETED","sponsor":"University of Fribourg","startDate":"2022-05-02","conditions":["Healthy"],"enrollment":45,"completionDate":"2025-03-12"},{"nctId":"NCT06899334","phase":"PHASE1","title":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-04-01","conditions":["Healthy"],"enrollment":24,"completionDate":"2026-08-01"},{"nctId":"NCT05976698","phase":"NA","title":"LSD-Perceptual-Choice-Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-02-26","conditions":["LSD Reaction"],"enrollment":30,"completionDate":"2025-02-25"},{"nctId":"NCT03781128","phase":"PHASE2","title":"Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-01-02","conditions":["Cluster Headache"],"enrollment":30,"completionDate":"2025-12"},{"nctId":"NCT05953038","phase":"EARLY_PHASE1","title":"LSD Occupancy of the Serotonin 2A Receptor in the Human Brain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-11-08","conditions":["Basic Science"],"enrollment":40,"completionDate":"2027-12-31"},{"nctId":"NCT06624137","phase":"","title":"Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-12","conditions":["OCD","Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD","PTSD - Post Traumatic Stress Disorder","Addiction","Tobacco Use Disorder","Obsessive Compulsive Disorder (OCD)","Opioid Use Disorder"],"enrollment":200,"completionDate":"2028-05"},{"nctId":"NCT05175430","phase":"PHASE1","title":"Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-10-24","conditions":["Healthy"],"enrollment":24,"completionDate":"2024-03-07"},{"nctId":"NCT04865653","phase":"PHASE1","title":"LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-03-17","conditions":["Healthy"],"enrollment":20,"completionDate":"2023-10-11"},{"nctId":"NCT04227756","phase":"PHASE1","title":"Comparative Acute Effects of LSD, Psilocybin and Mescaline","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-05-19","conditions":["Healthy"],"enrollment":32,"completionDate":"2022-09-02"},{"nctId":"NCT03790358","phase":"PHASE1","title":"Mood Effects of Serotonin Agonists","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-05-01","conditions":["Healthy"],"enrollment":80,"completionDate":"2023-01-27"},{"nctId":"NCT03934710","phase":"PHASE1","title":"Mood Effects of Serotonin Agonists Extended","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-04-20","conditions":["Healthy"],"enrollment":56,"completionDate":"2021-06-07"},{"nctId":"NCT05474989","phase":"PHASE2","title":"LSD Treatment for Persons With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Felix Mueller","startDate":"2024-06-01","conditions":["Alcohol Use Disorder (AUD)"],"enrollment":126,"completionDate":"2028-05-01"},{"nctId":"NCT00920387","phase":"PHASE2","title":"Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety","status":"COMPLETED","sponsor":"Multidisciplinary Association for Psychedelic Studies","startDate":"2008-02","conditions":["Anxiety"],"enrollment":12,"completionDate":"2012-09"},{"nctId":"NCT00566098","phase":"PHASE1,PHASE2","title":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-11","conditions":["Multiple Myeloma and Plasma Cell Neoplasm"],"enrollment":26,"completionDate":"2018-10"},{"nctId":"NCT05674669","phase":"PHASE1","title":"A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers","status":"COMPLETED","sponsor":"Eleusis Therapeutics","startDate":"2015-10-20","conditions":["Healthy"],"enrollment":32,"completionDate":"2017-07-17"},{"nctId":"NCT05670184","phase":"PHASE1,PHASE2","title":"The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality","status":"UNKNOWN","sponsor":"Maastricht University","startDate":"2023-01-01","conditions":["Prosocial Behavior"],"enrollment":60,"completionDate":"2024-01-01"},{"nctId":"NCT04516902","phase":"PHASE1","title":"Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-01-01","conditions":["Healthy"],"enrollment":24,"completionDate":"2022-08-22"},{"nctId":"NCT03153579","phase":"PHASE2","title":"LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-06-23","conditions":["Patients","Anxiety Disorders"],"enrollment":46,"completionDate":"2021-12-15"},{"nctId":"NCT04558294","phase":"PHASE1","title":"Effect of Ketanserin After LSD Administration","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-10-16","conditions":["Healthy"],"enrollment":24,"completionDate":"2021-09-29"},{"nctId":"NCT03604744","phase":"EARLY_PHASE1","title":"Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-03-27","conditions":["Healthy"],"enrollment":28,"completionDate":"2021-04-15"},{"nctId":"NCT01045460","phase":"PHASE2","title":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-01-15","conditions":["Multiple Myeloma"],"enrollment":36,"completionDate":"2020-06"},{"nctId":"NCT03207165","phase":"PHASE4","title":"Milrinone Versus Dobutamine in Critically Ill Patients","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-30","conditions":["Low Cardiac Output Syndrome","Cardiogenic Shock","Acute Coronary Syndrome","Pulmonary Edema"],"enrollment":192,"completionDate":"2020-06-12"},{"nctId":"NCT04421105","phase":"PHASE1","title":"A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years","status":"COMPLETED","sponsor":"Eleusis Therapeutics","startDate":"2015-06-29","conditions":["Healthy Volunteers"],"enrollment":48,"completionDate":"2015-11-05"},{"nctId":"NCT03321136","phase":"EARLY_PHASE1","title":"Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-11-28","conditions":["Healthy"],"enrollment":16,"completionDate":"2019-07-11"},{"nctId":"NCT03019822","phase":"EARLY_PHASE1","title":"Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-02-01","conditions":["Healthy"],"enrollment":28,"completionDate":"2018-09-04"},{"nctId":"NCT02451072","phase":"NA","title":"The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers","status":"COMPLETED","sponsor":"Psychiatric University Hospital, Zurich","startDate":"2015-03","conditions":["Healthy"],"enrollment":25,"completionDate":"2016-01"},{"nctId":"NCT01878942","phase":"EARLY_PHASE1","title":"Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-06","conditions":["Healthy"],"enrollment":16,"completionDate":"2014-12"},{"nctId":"NCT02308969","phase":"EARLY_PHASE1","title":"Neuronal Correlates of Altered States of Consciousness","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":["Healthy"],"enrollment":24,"completionDate":"2015-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"001637","UNII":"8NA5SWF92O","CHEBI":"CHEBI:6605","INN_ID":"729","UMLSCUI":"C0024334","ChEMBL_ID":"CHEMBL263881","DRUGBANK_ID":"DB04829","PDB_CHEM_ID":" 7LD","PUBCHEM_CID":"5761","SNOMEDCT_US":"15698006","IUPHAR_LIGAND_ID":"17","MESH_DESCRIPTOR_UI":"D008238"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":62,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb","pmid":"41213204","title":"Development and validation of a simple and fast method for routine analysis of new synthetic opioids and hallucinogens in whole blood using protein precipitation and UHPLC-MS/MS.","journal":"Forensic science international"},{"date":"2025 Oct 21","pmid":"40906494","title":"Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.","journal":"JAMA"},{"date":"2023 Dec","pmid":"37354215","title":"Ergometrine stimulates histamine H(2) receptors in the isolated human atrium.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2019 Jan","pmid":"30544085","title":"Use of the Randox Evidence Investigator immunoassay system for near-body drug screening during post-mortem examination in 261 forensic cases.","journal":"Forensic science international"},{"date":"2016 May","pmid":"27599655","title":"Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.","journal":"The Lancet. Infectious diseases"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1957-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}